1,708 reports of this reaction
2.2% of all ESTRADIOL TRANSDERMAL reports
#8 most reported adverse reaction
BREAST CANCER FEMALE is the #8 most commonly reported adverse reaction for ESTRADIOL TRANSDERMAL, manufactured by Amneal Pharmaceuticals NY LLC. There are 1,708 FDA adverse event reports linking ESTRADIOL TRANSDERMAL to BREAST CANCER FEMALE. This represents approximately 2.2% of all 79,078 adverse event reports for this drug.
Patients taking ESTRADIOL TRANSDERMAL who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is a less commonly reported adverse event for ESTRADIOL TRANSDERMAL, but still significant enough to appear in the safety profile.
In addition to breast cancer female, the following adverse reactions have been reported for ESTRADIOL TRANSDERMAL:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 1,708 FDA reports for ESTRADIOL TRANSDERMAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 2.2% of all adverse event reports for ESTRADIOL TRANSDERMAL, making it a notable side effect.
If you experience breast cancer female while taking ESTRADIOL TRANSDERMAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.